Larimar Therapeutics earnings were -$166.0M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest LRMR earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$29.6M, down 52.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, LRMR reported annual earnings of -$165.7M, with 105.5% growth. The next LRMR earnings date is Aug 13, 2026.
Larimar Therapeutics Earnings Reports & History FAQ
What were Larimar Therapeutics's earnings last quarter?
On LRMR's earnings call on May 7, 2026, Larimar Therapeutics (NASDAQ: LRMR) reported Q1 2026 earnings per share (EPS) of -$0.31, up 32.61% year over year. Total LRMR earnings for the quarter were -$29.61 million. In the same quarter last year, Larimar Therapeutics's earnings per share (EPS) was -$0.46.
The next LRMR earnings date is Aug 13, 2026. Add LRMR to your watchlist to be reminded of Larimar Therapeutics's next earnings date.
Is Larimar Therapeutics profitable or losing money?
As of the last Larimar Therapeutics earnings report, Larimar Therapeutics is currently losing money. Larimar Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$166.01 million, a 74.32% increase year over year.
What was LRMR's earnings growth in the past year?
As of Larimar Therapeutics's earnings date in May 7, 2026, Larimar Therapeutics's earnings has grown year over year. LRMR earnings in the past year totalled -$166.01 million.
What are Larimar Therapeutics's earnings expectations?
The current EPS estimate for Larimar Therapeutics's earnings report in Aug 13, 2026 is -$0.39.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.